詳細検索結果
以下の条件での結果を表示する: 検索条件を変更
クエリ検索: "ニコモ"
91件中 1-20の結果を表示しています
  • 関谷 敬三, 升野 博志, 奥田 拓道
    動脈硬化
    1982年 10 巻 2 号 229-234
    発行日: 1982/06/01
    公開日: 2011/09/21
    ジャーナル フリー
    A β-blockade, propranolol, was found to reduce lipogenesis from glucose stimulated by insulin in mice, suggesting that it inhibited an insulin action in vivo. When nicomol was administered with the blockade, its inhibitory action on insulin was remarkably relieved. It was demonstrated that propranolol also inhibited insulin-stimulated lipogenesis from glucose in isolated fat cells. In contrast to the in vivo experiments, nicomol did not relieve the inhibitory action on insulin in the fat cell system. On the other hand, nicotinic acid, one of metabolites of nicomol, was found to reduce the inhibitory action of propranolol on insulin. Then experiments were carried out to clarify the effect of micomol and its metabolites on PGI2 and TXA2 formation in the platelet rich plasma-arterial ring system. Nicomol was found to elevate PGI2 level and reduce TXA2 level in this system. On the other hand, nicotinic acid did not affect both PGI2 and TXA2 formation. Nicotinamide, one of metabolites of nicomol, increase PGI2 formation, but did not affect TXA2 content. Based on these experimental results, clinical effects of nicomol were discussed.
  • 澄田 道博, 大内 崇史, 奥田 拓道, 濱田 稔
    動脈硬化
    1984年 12 巻 4 号 839-843
    発行日: 1984/10/01
    公開日: 2011/09/21
    ジャーナル フリー
    An acid stable phosphoprotein was formed as a reaction intermediate of Ca2+-dependent ATPase of bovine aortic microsomes. The Ca2+-dependence of phosphoprotein formation was not affected by the addition of diltiazem (10μg/ml), nifedipine (100ng/ml), vanadate (10μM), nicotinic acid (10μg/ml) or nicotinamide (10μg/ml). Nccomol increased the phosphoprotein level at 1μM Ca2+. The rate of phosphoprotein formation was not changed, but the rate of its decomposition was decreased by 65% in the presence of 10μg/ml of nicomol. A high activity (3.89unit/mg) of adenylate kinase in the mitochondrial fraction isolated from bovine aortic smooth muscle was observed. The adenylate kinase activity was not affected by nicomol (10μg/ml) and nicotinamide (10μg/ml), but it was stimulated by 158% by 10μg/ml of nicotinic acid.
  • ―ニコモールの影響―
    石川 洋, 大沢 育子, 白井 厚治, 松岡 信夫, 斎藤 康, 吉田 尚
    動脈硬化
    1984年 12 巻 5 号 1117-1121
    発行日: 1984/12/01
    公開日: 2011/09/21
    ジャーナル フリー
    The mechanism, by which platelet aggregation was enhanced in hypercholesterolemic patients, was studied. When washed platelets were incubated with LDL, cholesterol content in platelets increased, while phospholipid content did not change, resulting in an increase of cholesterol/phospholipid ratio. These results indicated that the transfer of cholesterol occurred between LDL and platelets.
    Binding of 125I-LDL to platelets was observed at 4°C. It was reduced when cold LDL was added to the incubation mixture, suggesting that LDL bound to a specific binding site of platelets and changed platelet lipid composition.
    Next, the functional change of cholesterolenriched platelets was studied. Normal platelets and cholesterol-rich platelets were prelabeled with [1-14C] arachidonic acid and the release of arachidonic acid from them induced by thrombin was determined. Cholesterol-rich platelets released [1-14C] arachidonic acid more than normal platelets. These results suggested that phospholipase A2 activity was higher in cholesterol-rich platelets than in normal platelets, through which aggregation of cholesterol-rich platelets was enhanced compared with normal platelets. Nicomol reduced platelet aggregation at 1hr after administration in vivo, and it decreased binding of 125I-LDL to platelets in vitro. These results indicated that the transfer of cholesterol was reduced by nicomol, causing a decrease of platelet aggregation.
    Consequently, the mechanisms as follows were suggested. In hypercholesterolemic patients, increased LDL, which binds to specific binding sites of platelets, modifies the platelet lipid composition so as to increase cholesterol/phospholipid ratio of membrane. This change of lipid composition causes an increase in platelet phospholipase A2 activities, and resultant increase in arachidonic acid release enhances platelet aggregation.
  • 村井 淳志, 宮原 忠夫, 亀山 正邦, 神原 啓文, 河合 忠一
    動脈硬化
    1982年 9 巻 6 号 1067-1072
    発行日: 1982/02/01
    公開日: 2011/09/21
    ジャーナル フリー
    To assess the effects of nicomol, an ester derivative of nicotinic acid synthesized in Japan, on the lipoprotein abnormalities found in patients with ischemic heart disease, plasma lipoprotein fractions were ultracentrifugally separated and examined before and after three months administration of this drug in a dose of 1.2 grams a day.
    The subjects examined were 8 survivors of myocardial infarction and 6 patients with angina pectoris. Each fraction of ultracentrifugally separated VLDL and LDL was mixed with heparin Ca solution and then filtered with a Millipore filter. Fractions retained on the filter were used for the determination of their chemical composition. The HDL2 and HDL3 subfractions were delipidated with tetramethylurea and then electrophoresed on a polyacrylamide gel. The densitometry of these electrophoretograms permited us to determine the proportion of contaminating albumin.
    The plasma triglyceride level was significantly decreased, whereas the total cholesterol levels remained unchanged. VLDL-triglyceride concentration was significantly decreased. Percentage content of triglyceride was also significantly decreased but percentage contents of phospholipid and protein were significantly increased. The LDL level was almost unchanged. Either HDL-cholesterol level or HDL: LDL-cholesterol ratio was increased. Their increases were small but reached a statistically significant level. The HDL subfractions, HDL2 and HDL3-cholesterol levels were also increased. The increase of the former level was greater than that of the latter level, resulting in the slight increase of HDL2 to HDL3-cholesterol ratio. In the HDL2 subfraction, percentage contents of phospholipid and triglyceride were decreased whereas the percentage content of protein was increased. The percentage content of cholesterol remained unchanged. The chemical composition of HDL3 subfraction changed in almost the same way as that of HDL2 subfraction. No significant side effects were observed.
    It was clearly shown that nicomol administration considerably affected the lipoprotein profile in patients with ischemic heart disease. The level of VLDL was decreased in association with the significant elevation of the HDL, particularly HDL2-cholesterol level. Therefore, the changes in the lipoprotein profile found in the present study seem beneficial for protecting against the atherosclerotic vascular disease.
  • 藤木 精二
    医療
    1973年 27 巻 9 号 821-823
    発行日: 1973/09/20
    公開日: 2011/10/19
    ジャーナル フリー
  • 山崎 桂子, 高橋 雅人
    薬剤学
    1997年 57 巻 4 号 204-208
    発行日: 1997年
    公開日: 2019/05/24
    ジャーナル フリー

    Recently, nonprescription switch OTC drugs have attracted a great deal of attention, and many such drugs are being developed. Among these drugs, ibuprofen is contained in many brands and various dosage forms on the market. Dissolution tests were performed for ibuprofen preparations both by the paddle (PD) method described in the Japanese Pharmacopoeia (JP) and by the rotating dialysis cell (RDC) method. Dissolution behavior tested by the RDC method more accurately represented pharmaceutical characteristics of these preparations than that when tested by the PD method.

  • 澄田 道博, 奥田 拓道
    動脈硬化
    1983年 11 巻 3 号 557-559
    発行日: 1983/08/01
    公開日: 2011/09/21
    ジャーナル フリー
    Isolated dog cardiac microsomes (CSR) showed Ca2+ uptake by adding ATP, which was measured with the optical density change of Arsenazo III (Ca2+-sensitive dye) using Hitachi dual wave length spectro photometer at 30°C. Maximal Ca2+-uptake (18.5±1.4nmol/mg) was attained at 1min after adding 0.1mM ATP to 1 mg/ml of CSR in the presence of 50μM Arsenazo III. This Ca2+-uptake was inhibited by 0.5mM Nicomol (about 39%) and Nicotinic Acid Amid (about 28%) but not by Nicotinic Acid. It was suggested that the Nicomol and Nicotinic Acid Amid possibly delay the cardiac muscle contraction and relaxation.
  • 松本 忠雄
    産業医学
    1982年 24 巻 7 号 800-
    発行日: 1982/12/20
    公開日: 2018/12/30
    ジャーナル フリー
  • 岩崎 祥一, 鈴木 秀吉
    産業医学
    1982年 24 巻 7 号 800-
    発行日: 1982/12/20
    公開日: 2018/12/30
    ジャーナル フリー
  • 山本 章, 石川 勝憲, 松沢 佑次, 三杉 進
    動脈硬化
    1975年 3 巻 2 号 81-85
    発行日: 1975/07/01
    公開日: 2011/09/21
    ジャーナル フリー
    Nicomol [2, 2, 6, 6-tetrakis (nicotinyloxymethyl)-cyclohexanol], a derivative of nicotinic acid, was given to 25 patients with hyperlipidemia of type IIa, IIb or IV at a level of 0.6-1.2g per day for 8-32 months. Facial flush, erythema and itching of the skin temporarily occurred as side effects in 11 patients. Lowering of the plasma cholesterol level more than 50mg/100ml was attained in 35-50% of the cases. Decreases in plasma triglyceride concentration were observed in almost all of the cases of type IIb and IV in which the triglyceride level before treatment was more than 150mg/100ml. However, in several cases in which the triglyceride level was previously normal, that is, in type IIa hyperlipidemia, plasma triglyceride showed a slight or moderate increase and there was a change in lipoprotein lectrophoretic pattern from type IIa to type IIb or IV.
    In three cases of alcoholics (one female and two males) which presented type IIa or IIb hyperlipidemia before treatment, a sever hyperlipemia of type IV or V appeared during the course of the treatment. Prohibition of alcohol brought a prompt healing and the withdrawal of the drug also resulted in a recovery of plasma lipid level.
  • 石田 一夫, 黒瀬 真之輔, 石谷 康治
    医科器械学雑誌
    1972年 42 巻 10 号 678-679
    発行日: 1972/10/01
    公開日: 2020/10/19
    ジャーナル フリー
  • 金森 雅夫, 渡部 真也
    産業医学
    1982年 24 巻 7 号 800-801
    発行日: 1982/12/20
    公開日: 2018/12/30
    ジャーナル フリー
  • 宮下 和久, 潮見 重毅, 笠松 隆洋, 岩田 弘敏
    産業医学
    1982年 24 巻 7 号 799-800
    発行日: 1982/12/20
    公開日: 2018/12/30
    ジャーナル フリー
  • 山本 浩貴, 古田 善伯, 森 基要
    武道学研究
    1992年 25 巻 Supplement 号 49
    発行日: 1992年
    公開日: 2012/11/27
    ジャーナル フリー
  • 前田 明利
    有機合成化学協会誌
    2000年 58 巻 5 号 496-497
    発行日: 2000/05/01
    公開日: 2009/11/13
    ジャーナル フリー
  • 宮原 伸二
    日本農村医学会雑誌
    1981年 29 巻 6 号 843-858
    発行日: 1981/03/20
    公開日: 2011/08/11
    ジャーナル フリー
    The actual state of high density lipoprotein-cholesterol levels (in part, total cholesterol ratio) among rural inhabitants in Akita Prefecture is discussed in this report based on the findings of our extensive research work from basic statistics to experiments to improve the HDL-cholesterol level.
    In the basic study, we checked up on errors in measuring HDL-C levels or instrumental errors. Variations during a day (before, after eating), daily variations (five consecutive days) and seasonal variations (spring, summer, winter) were also examined. In actual fact, errors of measurement were not found, but significant errors caused by measuring instruments (precipitation method) were observed. There is no variation during a day. Daily and seasonal variations were significant.
    The mean value of HDL-C levels among 386 males examined was 57.5 mg/dl±14.7, while the mean value among 359 females was 55.2 mg/dl±14.0. A normal distribution with 50-59 mg/dl as the most commonly occurring values was shown in the frequency table for both sexes. By body build, obese persons, both male and female, showed significantly lower levels than the standard value.
    Geographical variations did not make any significant difference in the HDL-C level. However, the levels for those who engage in hard labor were high.
    By type of disease, the group of healthy, normal persons showed higher HDL-C levels than the groups of hypertension, cerebral apoplexy, hypercholesterolemia, hypertriglyceridemia, ischemic heart disease, liver ailment and anemia. There was no significant differential between the healthy normal group and the diabetes group.
    Retinal and electrocardiographical findings revealed that the normal group has higher levels than the abnormal group. It was also found that the HDL-C level has positive correlation with GOT and negative correlation with the triglyceride value.
    The HDL-C level was the highest among those who drink sake and do not smoke cigarettes, and the lowest among those who smoke but do not drink sake. The difference was significant. Linkings for coffee, juice and sweets did not affect the HDL-C level.
    A study was made of the changes in HDL-C levels in relation to drug administration and exercise.
    For eight weeks before administration, examinations were made to find changes in the HDL-C levels of healthy normal persons. However, their mean value did not fluctuate. Eight weeks after administration, it was found that the HDL-C levels of healthy, arteriosclerotic disease and hyperliPoproteinemia groups of persons rose significantly. Diabetics and cigarette smokers showed some improvement, thought not significantly.
    Exercise was rope skipping. The subjects were asked to do the light physical activity for four minutes a day over a period of four weeks. The experiment brought about significant improvements in the HDL-C levels.
  • 黒木 朋興
    フランス語フランス文学研究
    2006年 88 巻 169-
    発行日: 2006/03/01
    公開日: 2017/08/11
    ジャーナル フリー
  • ―三段階的適用決定法, 薬物選択法の試論―
    秦 葭哉
    動脈硬化
    1989年 17 巻 1 号 77-85
    発行日: 1989/04/01
    公開日: 2011/09/21
    ジャーナル フリー
    A three step regimen is proposed for treatment of hyperlipidemias. This is based on classifications of hyperlipidemias by degree of severity and antihyperlipidemic drugs according to their efficacy. Hyperlipidemias categorized as normal are TC<220mg/dl and/or TG<150mg/dl, 1st degree (mild) disorder 220≤TC<260mg/dl and/or 150≤TG<300mg/dl, 2nd degree (moderate) 260≤TC<300mg/dl and/or 300≤TG<750mg/dl, and 3 degree (severe): 300mg/dl≤TC and/or 750mg/dl≤TG. Antihyperlipidemic drugs are grouped as: a) lowering TC by 5% (γ-oryzanol, soysterol and melinamide) or TG by 15% (dextran sulfate, nicotinic acid derivatives and pantethine), b) reducing TC by 8% (nicotinic acid derivatives, clofibrate derivatives and pantethine) or TG 30% (clofibrate derivatives), and c) decreasing TC by 15% (probucol, cholestyramine), or TG by 50% (so far none).
    Indication for drug treatment is determined when a patient has 1st degree hyperlipisemia (s) with two or more risk factors (Indication I), or when the patient has 2nd degree hyperlipidemia (s) with one more risk factor (Ind. II), or when he or she has 3rd degree hyperlipidemia (s) (Ind. III). Selection criteria for the drug is primarily one drug from group a) for the indication (I), one from group b) for the indication (II), and one from group c) for the indication (III). If the first choice drug is not satisfactory, the second choice is another drug from the same group, or a combination of two drugs from the same group. If the second choice does not work, the third choice may be one from the group of drugs of higher efficacy, or a combination with a drug of higher class. The strategy of treatment is to lower the grade of disorders step by step, with the final aim levels of 190mg/dl for TC, 130mg/dl for TG, and 50mg/dl for HDL-cholesterol.
  • 小泉 弘
    國學院女子短期大学紀要
    1988年 6 巻 35-86
    発行日: 1988/03/20
    公開日: 2018/07/19
    研究報告書・技術報告書 フリー
  • 木村 昌彦, 田島 東海男, 中村 一成, 野瀬 清喜, 田中 昌也, 佐藤 宣践, 白瀬 英春, 山崎 俊輔, 高橋 進
    武道学研究
    1991年 24 巻 2 号 165-166
    発行日: 1991年
    公開日: 2012/11/27
    ジャーナル フリー
feedback
Top